Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.98 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals
MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors. 
Via Chartmill
Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic
Via Stocktwits
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
Via Stocktwits
Does This Move Make Merck Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
Merck & Co Unusual Options Activity For July 15
Via Benzinga
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
Via Stocktwits
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Via The Motley Fool
Topics Economy Intellectual Property
Want Decades of Passive Income? Buy This ETF and Hold It Forever
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
Via The Motley Fool
Topics Intellectual Property
P/E Ratio Insights for Merck & Co
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Dow Jones Stock to Target This Week and 2 to Avoid
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors. 
Via StockStory
Topics Stocks
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026. 
Via Benzinga
This House of Representative Just Bought Up To $30K In 3M Stock
Via Benzinga
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating. 
Via Benzinga
AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile. 
Via Benzinga
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals
MERCK & CO. (NYSE:MRK) offers a strong 4% dividend yield, consistent growth, and solid profitability, making it a top pick for income investors. The stock is also attractively valued. 
Via Chartmill
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
Kazia's early trial data show significant CTC and cluster reduction in a breast cancer patient treated with Paxalisib, Keytruda, and chemotherapy. 
Via Benzinga
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations. 
Via Benzinga
Topics World Trade
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
The takeover target just launched its first drug last summer. Shares have mostly trended higher since. 
Via Investor's Business Daily
Topics Government
Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline
Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion. 
Via Stocktwits
Topics Government
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.